Table 1. Open in new tab Details of...

First Author, Year (Reference No.)

No. of Patients (Male/Female)

Age (y) (Mean ± SD or Range)

Mean Follow-Up (mo)

Dosage (Mean or Range)

Disease Control^a (%)

PEG monotherapy

van der Lely et al., 2001 (12)

152 (85/67)

46 ± 14

19.6 mg/d

Rose and Clemmons, 2002 (21)

22–71

18–20 (range)

10–30 mg/d

Parkinson et al., 2002 (22)

20 (9/11)

59 ± 14

—

100

Sesmilo et al., 2002 (23)

48 (25/23)

45 ± 12

10–35 mg/d

Drake et al., 2003 (24)

7 (3/4)

59 ± 13

8^b

10–25 mg/d

—

Barkan et al., 2005 (25)

53 (27/26)

49 (23–81)

16 mg/d

Plockinger and Router, 2008 (26)

5 (2/3)

58 ± 14

10–25 mg/d

100

Ghigo et al., 2009 (27)

57 (28/29)

49 ± 14

5–35 mg/d

Trainer et al., 2009 (28)

25 (15/10)

49 (24–67)

5–30 mg/d

De Martino et al., 2010 (29)

11 (4/7)

44 ± 10

26.5 mg/d

Urbani et al., 2013 (17)

—

18.9 mg/d

—

Auriemma et al., 2012 (30)

19 (8/11)

44 ± 9

25.4 mg/d

Muhammad et al., 2016 (31)

15 (7/8)

35–80

80 mg/wk^b

Combination therapy PEG and SSAs

De Marinis et al., 2007 (32)

10 (5/5)

46 ± 8

OCT 40 mg/28 d, PEG 10–25 mg/d

—

Trainer et al., 2009 (28)

26 (17/9)

40 (24–65)

OCT 30 mg^b/28 d, PEG 5–30 mg/d

Madsen et al., 2011 (33)

12 (6/6)

55 ± 5

OCT 6.7–20 mg/28 d or LAN 24–60 mg/28 d, PEG 52.5 mg/wk^b

100

Urbani et al., 2013 (17)

—

OCT 30 mg/28 d or LAN 120 mg/28 d, PEG 10 mg/d

Auriemma et al., 2017 (34)

36 (14/22)

52 ± 10

78^b

OCT 30–40 mg/28 d or LAN 60–240 mg/28 d, PEG 30–280 mg/wk

Table 1.

Open in new tab

Details of Selected Studies

First Author, Year (Reference No.)	No. of Patients (Male/Female)	Age (y) (Mean ± SD or Range)	Mean Follow-Up (mo)	Dosage (Mean or Range)	Disease Control^a (%)
PEG monotherapy
van der Lely et al., 2001 (12)	152 (85/67)	46 ± 14	18	19.6 mg/d	57
Rose and Clemmons, 2002 (21)	5	22–71	18–20 (range)	10–30 mg/d	80
Parkinson et al., 2002 (22)	20 (9/11)	59 ± 14	10	—	100
Sesmilo et al., 2002 (23)	48 (25/23)	45 ± 12	18	10–35 mg/d	71
Drake et al., 2003 (24)	7 (3/4)	59 ± 13	8^b	10–25 mg/d	—
Barkan et al., 2005 (25)	53 (27/26)	49 (23–81)	8	16 mg/d	78
Plockinger and Router, 2008 (26)	5 (2/3)	58 ± 14	6	10–25 mg/d	100
Ghigo et al., 2009 (27)	57 (28/29)	49 ± 14	12	5–35 mg/d	51
Trainer et al., 2009 (28)	25 (15/10)	49 (24–67)	10	5–30 mg/d	60
De Martino et al., 2010 (29)	11 (4/7)	44 ± 10	18	26.5 mg/d	80
Urbani et al., 2013 (17)	18	—	6	18.9 mg/d	—
Auriemma et al., 2012 (30)	19 (8/11)	44 ± 9	18	25.4 mg/d	85
Muhammad et al., 2016 (31)	15 (7/8)	35–80	12	80 mg/wk^b	73
Combination therapy PEG and SSAs
De Marinis et al., 2007 (32)	10 (5/5)	46 ± 8	12	OCT 40 mg/28 d, PEG 10–25 mg/d	—
Trainer et al., 2009 (28)	26 (17/9)	40 (24–65)	10	OCT 30 mg^b/28 d, PEG 5–30 mg/d	73
Madsen et al., 2011 (33)	12 (6/6)	55 ± 5	6	OCT 6.7–20 mg/28 d or LAN 24–60 mg/28 d, PEG 52.5 mg/wk^b	100
Urbani et al., 2013 (17)	31	—	6	OCT 30 mg/28 d or LAN 120 mg/28 d, PEG 10 mg/d	42
Auriemma et al., 2017 (34)	36 (14/22)	52 ± 10	78^b	OCT 30–40 mg/28 d or LAN 60–240 mg/28 d, PEG 30–280 mg/wk	83

First Author, Year (Reference No.)	No. of Patients (Male/Female)	Age (y) (Mean ± SD or Range)	Mean Follow-Up (mo)	Dosage (Mean or Range)	Disease Control^a (%)
PEG monotherapy
van der Lely et al., 2001 (12)	152 (85/67)	46 ± 14	18	19.6 mg/d	57
Rose and Clemmons, 2002 (21)	5	22–71	18–20 (range)	10–30 mg/d	80
Parkinson et al., 2002 (22)	20 (9/11)	59 ± 14	10	—	100
Sesmilo et al., 2002 (23)	48 (25/23)	45 ± 12	18	10–35 mg/d	71
Drake et al., 2003 (24)	7 (3/4)	59 ± 13	8^b	10–25 mg/d	—
Barkan et al., 2005 (25)	53 (27/26)	49 (23–81)	8	16 mg/d	78
Plockinger and Router, 2008 (26)	5 (2/3)	58 ± 14	6	10–25 mg/d	100
Ghigo et al., 2009 (27)	57 (28/29)	49 ± 14	12	5–35 mg/d	51
Trainer et al., 2009 (28)	25 (15/10)	49 (24–67)	10	5–30 mg/d	60
De Martino et al., 2010 (29)	11 (4/7)	44 ± 10	18	26.5 mg/d	80
Urbani et al., 2013 (17)	18	—	6	18.9 mg/d	—
Auriemma et al., 2012 (30)	19 (8/11)	44 ± 9	18	25.4 mg/d	85
Muhammad et al., 2016 (31)	15 (7/8)	35–80	12	80 mg/wk^b	73
Combination therapy PEG and SSAs
De Marinis et al., 2007 (32)	10 (5/5)	46 ± 8	12	OCT 40 mg/28 d, PEG 10–25 mg/d	—
Trainer et al., 2009 (28)	26 (17/9)	40 (24–65)	10	OCT 30 mg^b/28 d, PEG 5–30 mg/d	73
Madsen et al., 2011 (33)	12 (6/6)	55 ± 5	6	OCT 6.7–20 mg/28 d or LAN 24–60 mg/28 d, PEG 52.5 mg/wk^b	100
Urbani et al., 2013 (17)	31	—	6	OCT 30 mg/28 d or LAN 120 mg/28 d, PEG 10 mg/d	42
Auriemma et al., 2017 (34)	36 (14/22)	52 ± 10	78^b	OCT 30–40 mg/28 d or LAN 60–240 mg/28 d, PEG 30–280 mg/wk	83

The percentage of disease control is expressed using the following criteria: normal IGF-1 levels adjusted to age and sex.

Median.

This Feature Is Available To Subscribers Only